Browsing Tag
gastrointestinal stromal tumors
2 posts
Could three FDA submissions turn bezuclastinib into a rare disease and oncology launch engine?
Cogent’s AdvSM NDA gives COGT a third bezuclastinib FDA submission, sharpening its KIT-driven disease franchise and late-2026 launch story.
Why oncology investors are watching Cogent Biosciences, Inc.’s PEAK data closely
Why investors are closely watching Cogent Biosciences’ PEAK data and what bezuclastinib could mean for valuation, revenue growth, and oncology market sentiment.